Semma Therapeutics Inc. has raised $114 million in a series B financing aimed at carrying its stem cell-derived beta cells, a potential therapy for people living with type 1 diabetes, through proof-of-concept studies. The company is preparing to file an investigational new drug (IND) application for the program while also exploring additional applications for its technologies.
Highly Oversubscribed Financing Brings Together Leading Syndicate of Investors to Advance Clinical Development of Novel Cell Therapy for Type 1 Diabetes
CAMBRIDGE, Mass., November 30, 2017 – Semma Therapeutics, a biotechnology company focused on the development of novel regenerative medicines, announced today the successful completion of a highly oversubscribed $114 million Series B financing. Proceeds will be used to bring Semma’s lead development program, encapsulated stem cell-derived islets, through clinical proof-of-concept in patients and to continue exploration of other regenerative medicine therapeutics. Semma’s proprietary technologies enable the generation of billions of functional, insulin-producing beta cells which have the potential to control blood sugar in people living with diabetes.
CAMBRIDGE, Mass., October 4, 2017 – Semma Therapeutics, a biopharmaceutical company developing stem cell-derived islet (SC-islet) technology for type 1 diabetes (T1D), today announced it will present on its encapsulated stem cell-derived human islets in a company overview at the Cell & Gene Meeting on the Mesa at 9:30 a.m. PDT on Thursday, Oct. 5 in La Jolla, California.
CAMBRIDGE, Mass., March 22, 2017 – Semma Therapeutics, a biopharmaceutical company developing Stem Cell-derived Islet therapy for type 1 diabetes (T1D), today announced it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities. Financial terms of the investment were not disclosed.
CAMBRIDGE, Mass., November 7, 2016 – Semma Therapeutics, a biopharmaceutical company developing cellular therapies for the treatment of diabetes, announced today that Mark Fishman, M.D., has joined its Board of Directors as Chairman.
CAMBRIDGE, Mass., September 12 th , 2016 – Semma Therapeutics, a biopharmaceutical company developing cellular therapy for diabetes, announced today that it has accepted a $5 million grant from the California Institute of Regenerative Medicine (CIRM). The award provides funding to develop personalized cell therapy for the treatment of diabetes. Diabetic patients’ own cells will be collected, transformed first into stem cells and then differentiated into stem-cell derived pancreatic islets (SC-islets) to use as an investigational cell therapy for diabetes.
When his son Sam was diagnosed with type 1 diabetes at six months of age, Doug Melton was incredulous. “I remember at night, my wife and I pricking his heel, and saying ‘No, this can’t be, this can’t be,’” he says. “It felt like we had lost the lottery.”
In a step that could lead to a new diabetes treatment, several Boston-area hospitals have teamed up with the Harvard Stem Cell Institute and biotech Semma Therapeutics to make personalized cell-based therapies and organize clinical trials.
The Harvard Stem Cell Institute (HSCI), three of Harvard’s clinical affiliates, and a biopharmaceutical company have formed an unusual collaboration to establish the Boston Autologous Islet Replacement Program (BAIRT) to accelerate a cure for diabetes.
A Cambridge, Mass., company, Semma Therapeutics, has acquired Providence-based CytoSolv, Inc., which has garnered local support since its founding in 2010 from the Slater Technology Fund and others, Slater announced Monday.
Semma aims to create a beta cell device implant for Type 1 diabetes patients that could provide them with 5 to 7 years of insulin independence. The notion of beta cell replacement therapy is not a new one. The breakthrough that led to the creation of Semma was the ability to generate sufficient and well-functioning human pancreatic beta cells from undifferentiated pluripotent stem cells.
CAMBRIDGE, Mass., March 18, 2015 – Semma Therapeutics, a company developing a cell therapy for Type 1 diabetes, announced today that it has closed a $44 million Series A consisting of equity financing and strategic funding. The Series A financing is led by MPM Capital, with Fidelity Biosciences, ARCH Venture Partners, and Medtronic participating. Alongside the equity financing, Semma entered into an undisclosed agreement with Novartis Pharmaceuticals.
In this article published by Pagliuca et al., scientists describe how to generate functional human pancreatic beta cells from stem cells.